How many nephrons are present in each kidney?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Nephron Number Per Kidney

Each human kidney contains approximately 900,000 to 1,000 nephrons on average, though individual variation is substantial, ranging from approximately 200,000 to over 2.5 million nephrons per kidney 1.

Key Points About Nephron Endowment

Average and Range

  • Mean nephron number: ~900,000-1,000 per kidney 2
  • Individual variation: 200,000 to >2.5 million nephrons per kidney 2
  • This represents a greater than 10-fold variation between individuals in the general population

Age-Related Changes

The number of nephrons changes substantially across the lifespan:

  • Young adults (18-29 years): Mean of 990,661 nonsclerotic glomeruli per kidney 3
  • Older adults (70-75 years): Mean of 520,410 nonsclerotic glomeruli per kidney 3
  • This represents a 48% decrease in functioning nephrons with aging 3

Pediatric Population

Recent data from pediatric nephrectomy specimens shows:

  • Median nephron number: 925,000 per kidney (IQR: 845,000-1,020,000) 4
  • Nephron number correlates with age at measurement and body surface area 4

Clinical Significance

Critical Mass Threshold

Renal function begins to decline when nephron mass falls below approximately 500,000 nephrons 5. This "critical mass" represents the point where compensatory mechanisms by remaining nephrons become insufficient.

No Regeneration

Nephrons cannot regenerate after approximately 36 weeks gestation 2, 6. All nephron formation is complete before birth, making congenital nephron endowment a lifelong determinant of kidney health.

Individual Susceptibility

Individuals born with nephron numbers on the lower end of the distribution (closer to 200,000-500,000 per kidney) face:

  • Higher risk of obesity-associated kidney disease 1
  • Greater susceptibility to hypertension-related kidney injury 1
  • Reduced capacity to compensate for additional nephron loss from acute kidney injury or chronic disease 2

Common Pitfalls

Do not assume nephron number reflects kidney size or cortical volume alone. Cortical volume decreases by only 16% between young and old adults, while nephron number decreases by 48% 3. This discrepancy occurs because:

  • Globally sclerotic glomeruli undergo atrophy and reabsorption
  • Remaining nephrons undergo compensatory hypertrophy
  • These processes mask the true extent of nephron loss

Avoid equating total GFR with nephron number. Total GFR is the product of nephron number multiplied by single-nephron GFR 5. Compensatory increases in single-nephron GFR can maintain total GFR despite substantial nephron loss, particularly in early disease stages.

Related Questions

Is it appropriate to give prophylactic nitrofurantoin (Macrobid) 100 mg twice daily to a patient with stage 4 chronic kidney disease (eGFR ≈ 15–29 mL/min)?
Can rivaroxaban (Xarelto) 2.5 mg be used in a patient with a serum creatinine of 215 µmol/L (impaired renal function)?
What is the appropriate ciprofloxacin dose for an adult with chronic kidney disease?
What medications are appropriate for treating severe nausea and vomiting in a 68-year-old patient with end-stage renal disease and a serum creatinine of 10 mg/dL?
Can denosumab be administered to a 75-year-old female with reduced estimated glomerular filtration rate (eGFR)?
Is drinking a glass of wine beneficial for heart health?
What anticholinergic medications for overactive bladder have the least central nervous system effects?
What analgesic and treatment options are appropriate for severe degenerative joint disease (osteoarthritis) in a patient with chronic kidney disease stage 3?
What questions should I ask a patient with an elevated mean corpuscular volume (MCV)?
Why is the free thyroxine low in a patient taking levothyroxine 137 µg, with an elevated free triiodothyronine on liothyronine 50 µg and a suppressed thyroid‑stimulating hormone?
Given a patient who is heterozygous for MTHFR C677T, heterozygous for ADRA2A -1291G>C, HTR2A G/G, SLC6A4 L/S, a CYP2D6 *4/*41 poor metabolizer, CYP1A2 -163A/A (highly inducible), and extensive metabolizer for CES1A1, CYP2B6, CYP2C19, CYP2C9, CYP3A4, UGT1A4, and UGT2B15, what pharmacogenetic‑guided medication plan—including ADHD and depression treatment, folate supplementation, and dermatologic risk considerations—should be recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.